Investor Ideas #Potcasts 526, #Cannabis News and #Stocks on the Move; (TSX.V: $FLWR.V) (OTC: $FLWPF) (Nasdaq: $JAZZ) (Nasdaq: $GWPH) (NYSE: $MJ)
Delta, Kelowna, BC, February 3, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/02031FLWR-JAZZ-GWPH-MJ.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we will be looking at a few public and private company announcements.
Dynaleo, Canada’s highest-capacity manufacturer of premium cannabis-infused soft chews, today announced the launch of two brands – Sunshower and DYNATHRIVE CBD. The two new brands are available in authorized retail locations and online channels in British Columbia and Saskatchewan, with plans to expand to Alberta, Ontario and additional regions in the near future.
Sunshower will launch with three delicious flavours (Watermelon Lemonade, Mango Tangerine, and Wild Strawberry) with each pack containing 5 pieces and 10 mg total THC. Sunshower is aimed at adults looking for an enjoyable and consistent THC experience with the finest flavours and ingredients. Inventory in Saskatchewan, the first province to place orders, has already sold out two shipments in its first month.
DYNATHRIVE CBD is Canada’s first and only large format CBD soft chew. Our first flavour, Apple Cider Vinegar, is made with purified CBD isolate, Canadian apple juice and real apple cider vinegar to deliver a sweetly refreshing, tart taste. The first DYNATHRIVE CBD format contains 30 pieces, perfect for daily supplements, with 300mg total CBD and is aimed at the growing segment of wellness consumers who are seeking a more enjoyable and convenient way to take CBD. The company has also formulated several additional flavours and unique product formats for launch later in 2021 to compliment these initial offerings.
“We continue to see accelerating demand in the edibles market for high-quality recreational and wellness cannabis products, especially from those who want to experience cannabis without needing to inhale. At the same time, consumers and retailers are experiencing inconsistent supply, both in terms of quantity and quality. As Canada’s highest-capacity soft chew manufacturer, we are in a unique position to have our products available at all times to consistently meet consumer demand with a best-in-class experience,” says Dynaleo Executive Chairman Michael Krestell.
Krestell continues, “In terms of the wellness consumer, countless customers have made it clear that they want CBD but without the intoxicating effects of THC. The 2- or 5-piece CBD offerings in the market today do not match up well for customers looking to take CBD on a daily basis or even throughout the day. The DYNATHRIVE CBD 30-piece pack is the perfect solution for them.”
The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) provided commentary on the decision by INFARMED, I.P. (“INFARMED”), Portugal’s National Authority of Medicines and Health Products, to approve the first market authorization which will allow a licensed producer of medical cannabis to release products in Portugal.
“We applaud the decision by INFARMED, which was the first of its kind, to allow patients to have access to medical cannabis products in Portugal through indication-specific market authorizations. The Portuguese government is forward thinking in its approach to improving the quality of life for Portuguese patients as scientific data continues to mount regarding medical cannabis as both safe and efficacious in treating a variety of conditions,” commented Pauric Duffy, Flowr’s Managing Director of Europe. “This ground-breaking decision sets the stage for Flowr to pursue market authorizations to serve Portuguese and European patients with medical cannabis produced from our world class local facilities in Sintra and Aljustrel,” commented Lance Emanuel, President and Interim CEO of Flowr.
In March 2020, Flowr announced that its wholly-owned subsidiary in Europe, Holigen Holdings Limited (“Holigen”), received its Good Manufacturing Practice (GMP) certification in accordance with European Union standards, for its indoor manufacturing facility located in Sintra, Portugal. The GMP certification was issued by INFARMED. Holigen is in the process of conducting stability testing on certain of its high-THC genetics and expects results within 2021.
Located just outside of Lisbon, Holigen’s Sintra facility is a purpose-built facility with six grow rooms, a research and development lab and an expected extraction processing facility. The Sintra facility is capable of producing approximately 2,000 kilograms of premium dried flower when fully optimized. Holigen’s European operations also include the Aljustrel facility which has more than 5,000,000 square feet of outdoor grow space and greenhouse capacity, capable of producing in excess of 500,000 kilograms of cannabis when fully operational.
Tikun Olam Cannbit (TASE:TKUN) reports that its international arm, Cannabit Ltd., will be the exclusive supplier of medical cannabis for clinical research into treatment for opioid addiction. The company will be entitled to exclusive marketing of the treatment method in Israel, Germany and England too.
The study will be done using a patent for an addiction treatment method that is currently undergoing registration by JFM Technology Holdings LLC, for which Opiostop has received an exclusive, unlimited license, under the U.S. FDA's fast-track.
The U.S. company Opiostop will provide all the financing, the submission of the patent and follow-up submissions, will be responsible for the performance and financing of the clinical trial in the United States, and will see to getting all the licenses for importing into the United States.
The treatment method may affect the market of opioid sales in the United States, which is estimated at about $20,000,000,000 (twenty billion dollars) per year.
After his daughter died as a result of opioid addiction, and his son also became addicted to analgesics, Jonah Rosenblatt, the founder of Opiostop, developed a special, three-stage method for withdrawal from opioids. The stages include, among other things, using approved drugs – synthetic and semisynthetic opioids – combined with treatment using medical cannabis.
Rosenblatt has already filed a patent for the method, and the company is now working on raising capital and starting clinical trials in the United States, with the intent of conducting clinical trials, submitting and approving the treatment through the FDA's fast-track.
Avinoam Sapir, the CEO of Tikun Olam-Cannabit states: "Rosenblatt's opioid method of treatment is on the FDA's fast-track for approval, in order to solve the problem of severe addiction to opioids that has been sweeping through the United States in recent years. Every 17 minutes, someone dies in the United States of an analgesic overdose. Tikun Olam–Cannabit is happy to be part of the possible solution to this severe 'plague' of analgesic addiction, a problem that can be identified here in Israel too."
Jonah Rosenblatt, the CEO of Opiostop states: "Over 70,000 Americans, and half a million people worldwide die each year from the Opioid Epidemic. This is ripping apart the fabric of society. We believe that combining our Multi-modal approach to curing addiction with CANNBIT'S Cannabinoid based medications & formulations. As the Clinical research of Medical Cannabis has been shown to reduce opioid dependency. By coming together in this JV, together we are extremely confident in our combined effort to reach our goal of giving people back their free will.”
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021.
Upon close of the transaction, the combined company will be a leader in neuroscience with a global commercial and operational footprint well positioned to maximize the value of its diversified portfolio.
GW is a global leader in discovering, developing, manufacturing and commercializing novel, regulatory approved therapeutics from its proprietary cannabinoid product platform to address a broad range of diseases. The company's lead product, Epidiolex® (cannabidiol) oral solution, is approved in patients one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome and Tuberous Sclerosis Complex (TSC), all of which are rare diseases characterized by severe early-onset epilepsy. Epidiolex was the first plant-derived cannabinoid medicine ever approved by the U.S. Food and Drug Administration (FDA). This product has also been approved, under the tradename Epidyolex®, by the European Medicines Agency (EMA) in patients two years of age and older for the adjunctive treatment of seizures associated with LGS and Dravet syndrome in conjunction with clobazam and is under EMA review for the treatment of seizures associated with TSC. In addition to the approved indications for Epidiolex, there are considerable opportunities to pursue other indications within the epilepsy field, including other treatment-resistant epilepsies where significant unmet needs of patients exist.
Beyond Epidiolex, GW has a scientific platform and deep innovative pipeline of cannabinoid product candidates, as well as highly specialized manufacturing expertise, developed over two decades of pioneering and building leadership in cannabinoid science. This pipeline includes nabiximols, for which the company is in Phase 3 trials to seek FDA approval for treatment of spasticity associated with multiple sclerosis and spinal cord injury, as well as earlier-stage cannabinoid product candidates for autism and schizophrenia.
"Jazz is proud of our leadership position in sleep medicines and rapidly growing oncology business. We are excited to add GW's industry-leading cannabinoid platform, innovative pipeline and products, which will strengthen and broaden our neuroscience portfolio, further diversify our revenue and drive sustainable, long-term value creation opportunities," said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals. "We are joining two teams that share a passion for, and track record of, developing differentiated therapies that advance science and transform the lives of patients. This will help facilitate a successful integration and bring added capabilities to Jazz. Given the strength of our balance sheet and the meaningful financial drivers of the transaction, we are confident in the value we can deliver to both companies' shareholders and patients. We look forward to welcoming the GW team to Jazz to build an even stronger company."
"Over the last two decades, GW has built an unparalleled global leadership position in cannabinoid science, including the successful launch of Epidiolex, a breakthrough product within the field of epilepsy, and a diverse and robust neuroscience pipeline. We believe that Jazz is an ideal growth partner that is committed to supporting our commercial efforts, as well as ongoing clinical and research programs," said Justin Gover, CEO of GW Pharmaceuticals. "We have a shared vision of developing and commercializing innovative medicines that address significant unmet needs in neuroscience and an approach of putting patients first. Together, we will have an opportunity to reach and impact more patients through a broader portfolio of neuroscience-focused therapies than ever before."
Jason Wilson, cannabis and banking expert at ETF Managers Group (NYSE: MJ) commented on this recent acquisition as well as the recent trends in the cannabis space saying “Jazz Pharma’s acquisition of GW Pharma, at a significant premium, demonstrates that pharmaceutical companies are recognizing the value and future potential of cannabinoid based medicines. It is also another example that the cannabis industry is continuing to normalize and evolve beyond the traditional cultivation of flower, with potential well outside of our borders. For investors, the acquisition of GW Pharma is another reminder that investing in cannabis touches many verticals globally, requiring a diverse approach beyond traditional cannabis cultivation companies.”
Mr Wilson continued to discuss some of the other factors behind the recent rally in cannabis stocks, such as “domestically, Senate Majority Leader Schumer has confirmed that cannabis reform legislation will be a key priority in the current Congress, and that it will include sensible tax and regulatory oversight at the federal level along with criminal justice reform; Globally, Mexico recently published its federal medical cannabis regulations, and the UN voted to remove medical cannabis from its list of dangerous narcotics. These recent catalysts occurred on the backdrop of strong global cannabis sales growth in 2020 (2020 global sales are expected to reach approximately $20 billion – an increase of approximately 35% versus 2019 sales of $15 billion) and suggest that the industry will continue to see strong growth and continued expansion domestically and globally for the foreseeable future. MJ’s diversified cannabis portfolio has benefitted from these recent global and domestic catalysts (up 90%+ in the previous three months, 40%+ YTD), and remains well positioned to take advantage of what is expected to be one of the fastest growing global industries over the next decade.”
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory